interferon (BetaJect / BetaJect Light / Extavia)

✓ Approved

Warner Chilcott PLC · IFNAR2 · Recombinant Proteins

What is interferon?

interferon is a recombinant proteins developed by Warner Chilcott PLC. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand Names	BetaJect, BetaJect Light, Extavia
Company	Warner Chilcott PLC
Drug Class	Recombinant Proteins
Molecular Target	IFNAR2
Route	Injectable (Others), Subcutaneous Injection
Status	Approved

Sources: ClinicalTrials.gov, Warner Chilcott PLC

Mechanism of Action

Molecular Targets

interferon acts on 1 molecular target:

IFNAR2

interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)

Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

interferon is developed for 4 unique indications across 2 therapeutic areas.

Therapeutic Area	Condition	Phase
Nervous system disorders	Relapsing-remitting multiple sclerosis	✓ Approved
Nervous system disorders	Secondary progressive multiple sclerosis	✓ Approved
Nervous system disorders	Primary progressive multiple sclerosis	Phase II
Infections and infestations	Acquired immunodeficiency syndrome	Preclinical